NIH-CAP Company Descriptions 2009-10
Accelerator Commercialization Track (ACT)
Advanced Liquid Logic, Inc.Durham, NC
Industry Sector: Diagnostics
Website: / Richard West
CEO
Tel: 919-287-9010
Email:
Advanced Liquid Logic transforms Lab-on-a-Chip from “in the Lab” to “Anywhere” rapidly advancing the “Digital Microfluidics technology”. Instead of mechanical pumps and valves, electronics are used to directly control fluid operations, enabling systems to be smaller, less expensive and more flexible than ever before. Immunoassays, PCR, clinical chemistry, sample preparation and more can be performed on the same flexible proprietary platform and chip. Assays are performed in minutes--with the sensitivity and precision of state-of-the-art laboratory instruments. A compact benchtop immunoassay analyzer has been developed and is currently being evaluated by key partners. The development of other assay formats as well as a portable analyzer is underway.
Biomedica Management Corp
Brooklyn, NY
Industry Sector: Pharmaceuticals
Website: / George Falus
CEO
Tel: 212-719-4799
Email:
Biomedica Management Corporation is a research and development company headquartered at the SUNYDownstateBiotechCenter in Brooklyn, with biochemistry labs at the UMBC TechCenter in Baltimore. The company, formed in 1999, explores and develops critical technologies in collaboration with academic scientists. The company is developing novel treatments in inflammation, sepsis, and wound healing with civilian and military applications, which address serious unmet medical needs.Its leading technology, ClotFoam, is a hemostatic agent for use in non-compressible high-volume hemorrhage with important applications in trauma, laparoscopic surgery and wound healing. Second in the pipeline is a glycolipid for the treatment of sepsis
CHI Systems Incorporated
Ft. Washington, PA
Industry Sector: Other
Website: / Wayne Zachary
CEO
Tel: 215-542-1400 x141
Email:
CHI Systems creates decision-support and training systems that are usable, intuitive, and effective for individuals and the organizations in which they work. We apply our proprietary computational models of human cognition, personality, and emotion to build virtual environments in which decision makers can learn and practice complex clinical, teamwork and communication skills. Our medical simulation product TEACH, for example, helps clinicians develop and hone culturally appropriate communications skills for patient communication in oncology. In TEACH, clinicians interact with virtual standardized patients, each distinct cultural backgrounds and individual personalities, in realistic clinical encounters and receive customized coaching and feedback.
CFD Research Corporation
Huntsville, AL
Industry Sector: Research Tool
Website: / Ashok Singhal
CEO
Tel: 256-726-4829
Email:
CFDRC specializes in engineering simulations and innovative designs for Aerospace, Defense, Biomedical and Energy applications. Using our software and experimental facilities, we develop new hardware concepts, innovative designs, and prototypes. The Biomedical Technology branch of CFDRC develops innovative products and solutions for critical needs such as: (a) Microfluidics and nanotechnology for environmental, biological and clinical diagnostics, (b) Integrative bioinformatics and systems biology software tools for personalized healthcare, and (c) Micropower technologies for sensors and implantable medical devices.
Boston Micromachines Corporation
Cambridge, MA
Industry Sector: Medical Devices
Website: / PaulBierden
CEO
Tel: 617-688-4178
Email:
Boston Micromachines Corporation (BMC) is the leading provider of advanced microelectromechanical systems (MEMS)-based mirror products used in commercial adaptive optics systems. By applying wavefront correction to produce high resolution images, BMC devices can be used for imaging biological tissue and the human retina and to enhance images blurred by the earth's atmosphere. The company's suite of award-winning compact DM products is the most cost-effective, highest performance mirrors in the market. They are widely used to drive scientific discovery in microscopy, astronomy, and vision science. Customers include NASA, UC Berkeley, Lockheed Martin and BostonUniversity. BMC also offers custom-designed manufacturing services.
Conversion Energy Enterprises, Inc.
Spring Valley, NY
Industry Sector: Pharmaceuticals
Website: conversionenergy.com / BarbaraSoltz
CEO
Tel: 845-425-9170
Email:
CEE is an innovation-driven, medical technology company, developing specialty surgical devices and biologics. Its mission is to provide systems to the medical community based on proprietary laser technology and light activated biomaterials.
New Health Sciences inc
Bethesda, MD
Industry Sector: Medical Devices
Website: / MartinCannon
CEO
Tel: 240-475-0181
Email:
NHSi is developing and commercializing technologies in to two intereralted categories -- hemodynamic products and hematology products. The hemodynamic products include: hemodynamic vascular analysis (HVA) a method on analysing doppler data to assess the health of blood vessels in the brain; webTCD an method of managing transCranial Doppler data more efficiently; and sonAP, a non-invasive and precise measure of ABP. Hematology products include HASP an anaerobic blood storage device the extends the shelf life of stored RBC's and improves their therapeutic quality and MCA which measures the deformability and other therapeurtically relevant propoerties of stored RBC's.
Orthogen, LLC
Springfield, NJ
Industry Sector: Medical Devices
Website: / Harold Alexander
CEO
Tel: 973-467-2404
Email:
Orthogen LLC was spun off from its corporate parent, BioLok International, Inc, in October 2007. As a BioLok division, Orthogen previously developed the LaserLok ™ line of dental implants and calcium sulfate-based bone graft materials. The new company retains intellectual property rights for new generations of bone graft products, bioreactors, "smart" transcutaneous prostheses, orthopedic implants, cardiac stents and intraocular lenses. Orthogen is currently researching and scaling up these technologies. In the near term, Orthogen LLC is developing and marketing a new line of completely resorbable synthetic bone graft products for dental applications trade- named DentoGen™. Presently, Orthogen is clinically testing a novel, patented nanocomposite bone graft material, DentoGen-CR, that undergoes controlled degradation in the body and stimulates bone regeneration as it degrades. This nanocomposite, allowed for marketing by US FDA, will be launched in the fourth quarter of 2009. A first generation bone graft material, DentoGen™, was launched in 2008.
OsteoGeneX Inc
Kansas city, KS
Industry Sector: Pharmaceuticals
Website: / DebraEllies
CEO
Tel: 816-509-6510
Email:
We develop phamaceuticals which build new bone for treatment of osteoporosis, spinal fusion, or fracture repair.
Quintessence Biosciences, Inc.
Madison, WI
Industry Sector: Biotechnology
Website: / Laura E. Strong, Ph.D.
President and Chief Operating Officer
Tel: 608-441-2950
Email:
Quintessence Biosciences is a private, clinical stage biopharmaceutical company developing novel, proprietary, anti-cancer compounds based on its EVade™ ribonuclease technology platform. Quintessence’s first product candidate, QBI- 139, is in a Phase I clinical trial at the University of Wisconsin Comprehensive Cancer Center. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. The company is currently working to generate financial support to fund the next stage of clinical development of QBI-139 and further the development of other compounds in the pipeline.
Resodyn Corporation
Butte, MT
Industry Sector: Biotechnology
Website: / Larry Farrar
CEO
Tel: 406-497-5252
Email:
Resodyn Corporation's vision is to be a recognized, world-class leader in providing innovative technical solutions. Our passion for technology and commitment to progress is conveyed in our mission statement, Building Value through Discovery and Innovation®. In addition to our established Business Units, Resodyn Corporation is continuing to develop other advanced technology and products based upon our core technologies in the areas of Mixing Technology , Separations Technology , Cell-Culturing Reactors , Tissue Engineering , Thermal Processing Technologies and Processing Technologies for Renewable Resources
Robin Medical, Inc.
Baltimore, MD
Industry Sector: Medical Devices
Website: / Erez Nevo
CEO
Tel: 443-450-4030
Email:
Robin Medical is a medical technology incubator company founded in 1997 by physicians and engineers from the Johns Hopkins Hospital in Baltimore, Maryland. Our main focus is in the field of MR-guided interventions. Our primary product, the EndoScout® tracking system enables navigation of devices to their target under realtime MRI. It was developed during the years 2001-2004 with SBIR grant support and it is FDA-cleared to guide any surgical intervention. It is used for clinical and research applications in 12 leading clinical centers in the USA, Japan and Europe. Our mission is to provide the required tools to transform MRI from almost pure diagnostic modality into a commonly used interventional tool.
St Charles Pharmaceuticals
New Orleans, LA
Industry Sector: Pharmaceuticals
Website: / Kenneth Narducy
CEO
Tel: 408-219-8748
Email:
St Charles Pharmaceuticals (SCP) is developing a series of first-in-class analgesics. The Company’s first compound (oral SCP-1) is in Phase I human studies for acute pain. In 2008, the Company was awarded a 3-year $3 million NIH grant to fund the preclinical development of its second compound, SCP-123, for neuropathic pain. The first year of that grant was recently completed, resulting in the demonstration of oral efficacy in neuropathic pain models and safety in in vitro assays. SCP will next conduct the in vivo safety studies through CROs and subsequently prepare and submit the SCP-123 IND to the FDA.
SureGene, LLC
Louisville, KY
Industry Sector: Diagnostics
Website: / Mike Burke
CEO
Tel: 847-687-3873
Email:
SureGene, LLC utilizes modern genetic technology to discover the underlying genetic basis for psychiatric diseases. Our primary goal is to empower patients and physicians with knowledge to make the best possible healthcare decisions based on individual genetic profiles. SureGene, LLC will accomplish these goals through DNA-based diagnostic tests that predict drug response and aid in the diagnosis and classification of disease, such as the AssureGeneTM Test for Schizophrenia. As never before possible, this personalized approach to medicine should provide new options and increase the confidence and comfort level for patients, their families, and health care providers.
Swaasth Inc
Oklahoma City, OK
Industry Sector: Other
Website: / Rama Ramanujam
CEO
Tel: 405-297-8881
Email:
Swaasth Inc, provides high quality, cost-effective disease preventive dietary botanical agents. This is accompanied with gene-expression based quality assurance testing. The company plans to provide pharmaceutical and Ayurvedic preparations, natural product medicines, derived from plant, animal and microbial material. The company is prepared to provide alternative-medicine services of ‘structure-function’ assays, in vitro studies, in vivo studies, clinical trials, and drug design and testing. Strategically, without educated consumption of fruits, vegetables and spices and regular exercise, one would be at a serious disadvantage in dealing with diseases. National surveys indicate that more than half of adults in the United States take some form of dietary supplement. Botanical components comprise about 25 percent of the supplement market. These products are used by consumers to promote health and wellness, prevent and treat disease. Despite widespread use of dietary supplements with botanical components and promising science, quality assurance in this area has been relatively limited and unfocused. As a consequence, efficacy and safety of many widely used botanical components have not been adequately evaluated. The intense confusion of health benefits of foods and natural supplements requires constant quality assurance based on scientific analysis. Only rigorous scientific evaluation of botanicals will drive real growth and renewal of an enterprise. Swaasth Inc. will serve academic commercial and government clients to develop dietary botanical supplements based on gene expression quality testing.
Xcision Medical Systems LLC
Clarkesville, MD
Industry Sector: Medical Devices
Website: NA / ChristopherAmies
CEO
Tel: 443-982-5560
Email:
Our Company manufactures radiotherapy systems specifically created and optimized for treating early stage breast cancer. Our unique technology provides a new high quality treatment option that is effective, safe and convenient. Gamma Pod treatment is non invasive and reduces 7 weeks of treatment to as little as 3 visits to the clinic. This provides greater access for women to choose a path to breast conservation.
Tensegrity Prosthetics
Louisville, CO
Industry Sector: Medical Devices
Website: / Jerome Rifkin
CEO
Tel: 303-547-5738
Email:
Tensegrity Prosthetics, has created the first major non-robotic advance in prosthetic foot design in the past 25 years with a product that emulates the actions of the natural foot in walking. Tensegrity’s foot allows functional efficiencies that will enable many more lower limb amputees to enjoy more stability and freedom of mobility. This prosthesis gives them the opportunity to participate in more activities because it allows wearers to do more without tiring, compared to other prosthetic foot designs currently on the market. Tensegrity will succeed by creating win-win relationships throughout the value chain.
Vital Access
West Valley City, UT
Industry Sector: Medical Devices
Website: / Doug Smith
CEO
Tel: 801-443-9390
Email:
Vital Access is a medical device developer working to improve vascular access methods for patients, doctors, and nurses. Vital Access has developed a subcutaneous vascular access aid that is placed directly on a patient’s vasculature through novel and proprietary surgical and interventional methods. The subcutaneous vascular access aid will enable safer and more reliable chronic access, while reducing the occurrence of infections and other serious complications that require hospital referral. Hemodialysis access, drug delivery access for oncology, aquapheresis access, and general vascular access may all benefit from this advancement.
X-Ray Optical Systems, Inc.
East Greenbush, NY
Industry Sector: Research Tool
Website: / David Gibson
CEO
Tel: 518-880-1500
Email:
XOS is the leading global provider of x-ray optics and optic-based integrated solutions for material analysis. In addition, XOS is the market leader in providing fully intergrated solutions for the petroleum industry with its Sindie and Clora detectors which identify low concertratins of these elements in petroleum products including diesel, gasoline, biofuels, and crude.
Zacharon Pharmaceuticals, Inc.
San Diego, CA
Industry Sector: Pharmaceuticals
Website: zacharon.com / Robin Jackman
CEO
Tel: 858-768-7828
Email:
Zacharon is developing drugs that target glycans; a class of molecules with key roles in cancer and other diseases. Despite extensive evidence that glycans are excellent drug targets, few companies have successfully targeted glycans due to lack of effective preclinical drug discovery tools. Zacharon has overcome this challenge by creating proprietary assays for high-throughput screening of glycan targeted small molecule drugs, leaving an exceptional opportunity for a new class of therapeutics with little competition. This platform is being leveraged across a variety of cancers and other diseases, allowing the company to generate a portfolio of drug candidates. Zacharon intends to advance the drugs through Phase I clinical trials and then attract larger companies for advanced trials and marketing.
Commercialization Training Track (CTT)
Acelot, Inc.Santa Barbara, CA
Industry Sector: Pharmaceuticals
Website: / AmbujSingh
CEO
Tel: 805-617-3610
Email:
Acelot develops software for graph synthesis, querying, and mining with immediate applications to drug discovery. The combination of proven graph-based technology for mining data with flexible information integration and knowledge management will improve the efficiency of drug discovery pipelines in the pharmaceutical industry.
ADA Technologies, Inc.
Littleton, CO
Industry Sector: Research Tool
Website: adatech.com / CliftonBrown
CEO
Tel: 303-874-8264
Email:
ADA Technologies is a technology development and commercialization company. ADA commercializes technology in a number of different technical and market areas. This program is focused on the development of carbohydrate microarray slides, microarrays, services, and supporting products. ADA has been in business for 25 years and has spun out five companies and more than seven license agreements.
Adarza BioSystems Inc.
West Henrietta, NY
Industry Sector: Diagnostics
Website: / RandolphHenke
CEO
Tel: 585-214-2406
Email:
ADARZA BIOSYSTEMS is an early stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. Adarza’s proprietary chip-based platform, Arrayed Imaging Reflectometry (AIR), achieves high sensitivity by detecting intensity changes in images of antireflective chips functionalized with highly specific detection molecules (proteins, DNA, etc.). The AIR platform can perform sophisticated clinical tests within minutes and is a label free, fully arrayable technology that will potentially allow hundreds of tests to be run simultaneously on a single chip using a single sample.
Advanced Hearing Concepts
Bodega Bay, CA
Industry Sector: Other
Website: na / HarryLevitt
CEO
Tel: 707-875-2289
Email:
Company serves as a consultant to the Hearing Industry and Academia, and develops new technologies for hearing rehabilitation.
Aerodyne Research, Inc.
Billerica, MA
Industry Sector: Medical Devices
Website: / CharlesKolb
CEO
Tel: 978-663-9500 ext. 290
Email:
Aerodyne Research, Inc. has provided R&D services and products to commercial and government clients working to solve national and international problems since 1970. Areas of specialization include atmospheric research using advanced environmental monitoring instrumentation, remote sensing and image processing, novel energy sources, and computer modeling and simulation. Our breath analysis system for the study of respiratory diseases builds on our expertise in developing sensitive trace gas monitors. Over the past 8 years, Aerodyne has focused on developing commercial products and services from proprietary technologies. Product sales now account for 45% of revenue. Total company revenue and distribution is given below.
Aerophase
Longmont, CO
Industry Sector: Pharmaceuticals
Website: / BrianHansen
CEO
Tel: 303-651-1791
Email:
Aerophase, Inc. is a small research and development company that was founded in 1997 by Brian N. Hansen, PhD. The focus of the company is the development of drug delivery technologies that utilize supercritical fluid carbon dioxide as a process fluid. The overall strategy is to develop new drug aerosol systems, improve existing ones, reduce costs, and replace solvents and fluids that are hazardous to health and the environment. Aerophase has made significant strides towards developing a new, proprietary drug and device combination for the treatment of lung cancer with inhaled paclitaxel.